Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

Gianni, LLGianniCHIUN-SHENG HUANGEgle, DDEgleBermejo, BBBermejoZamagni, CCZamagniThill, MMThillAnton, AAAntonZambelli, SSZambelliBianchini, GGBianchiniRusso, SSRussoCiruelos, E ME MCiruelosGreil, RRGreilSemiglazov, VVSemiglazovColleoni, MMColleoniKelly, CCKellyMariani, GGMarianiDel Mastro, LLDel MastroMaffeis, IIMaffeisValagussa, PPValagussaViale, GGViale2022-04-152022-04-152022-02-1709237534https://scholars.lib.ntu.edu.tw/handle/123456789/604455High-risk triple-negative breast cancers (TNBCs) are characterized by poor prognosis, rapid progression to metastatic stage and onset of resistance to chemotherapy, thus representing an area in need of new therapeutic approaches. Programmed death-ligand 1 (PD-L1) expression is an adaptive mechanism of tumour resistance to tumour-infiltrating lymphocytes, which in turn are needed for response to chemotherapy. Overall, available data support the concept that blockade of PD-L1/programmed cell death protein 1 checkpoint may improve efficacy of classical chemotherapy.enatezolizumab; neoadjuvant therapy; triple-negative breast cancer[SDGs]SDG3Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized studyjournal article10.1016/j.annonc.2022.02.004351827212-s2.0-85126101192https://api.elsevier.com/content/abstract/scopus_id/85126101192